欢迎访问《中国真菌学杂志》杂志官方网站,今天是 分享到:

中国真菌学杂志 2022, Vol. 17  Issue (4): 278-282.

论著 上一篇    下一篇

两性霉素B治疗艾滋病合并隐球菌性脑膜脑炎40例临床特征及诊疗分析

霍琴, 刘敏, 杨红红, 刘倩, 吴玉珊, 李明俊, 石峰, 何坤   

  1. 重庆市公共卫生医疗救治中心感染科, 重庆 400036
  • 收稿日期:2021-09-06 出版日期:2022-08-28 发布日期:2022-08-31
  • 通讯作者: 何坤,E-mail:gspsjz@163.com E-mail:gspsjz@163.com
  • 作者简介:霍琴,女(汉族),本科,主管护师.E-mail:351562658@qq.com

Amphotericin B in the treatment of AIDS with cryptococcal meningitis clinical features, diagnosis and treatment of 40 cases

HUO Qin, LIU Min, YANG Honghong, LIU Qian, WU Yushan, LI Mingjun, SHI Feng, HE Kun   

  1. Chongqing Public Health Medical Center Infectious Disease, Chongqing 400036, China
  • Received:2021-09-06 Online:2022-08-28 Published:2022-08-31

摘要: 目的 分析两性霉素B治疗艾滋病合并隐球菌性脑膜脑炎的临床特点、药物治疗不良事件情况,寻找发生不良事件的相关危险因素,为隐球菌性性脑膜脑炎临床诊治提供参考。方法 回顾性分析我院2017年1月至2018年12月诊断为艾滋病合并隐球菌性脑膜脑炎住院患者基本资料,对实验室检测结果、药物治疗方案、不良事件等资料进行收集、分析。结果 40例艾滋病合并隐球菌性性脑膜脑炎患者平均年龄为(40.54±15.42)岁,住院天数为(32.67±12.22) d,颅内压升高30例(75.0%),脑脊液隐球菌抗原阳性37例(92.5%),脑脊液培养阳性31例(77.5%),脑脊液墨汁染色涂片阳性34例(85.0%),诱导期治疗方案选择两性霉素B联合氟胞嘧啶,在治疗过程中,发生不良事件最多的是贫血22例(55.0%),其次是低钾17例(42.5%);血红蛋白(hemoglobin,HGB)、血钾指标出现明显异常时间主要在药物使用的第2周,肌酐、总胆红素、谷丙转氨酶指标出现明显异常时间主要药物使用的第1周。两性霉素B累计使用剂量>500 mg、治疗前HGB<110 g/L是导致患者治疗疗程<14 d的影响因素,差异有统计学意义(P=0.001;P=0.006)。结论 艾滋病合并隐球菌性性脑膜脑炎患者在使用两性霉素B药物治疗过程中,不同时间点发生不良事件有所不同,影响药物使用天数的因素主要是药物累计使用剂量、治疗前HGB水平。

关键词: 两性霉素B, 隐球菌性脑膜脑炎, 不良事件

Abstract: Objective To analyze the clinical characteristics and adverse events of amphotericin B in the treatment of AIDS patients with cryptococcal meningitis, and to find out the factors risk adverse events, so as to provide reference for clinical practice. Methods The basic data of hospitalized AIDS patients with cryptococcal meningitis diagnosed in our hospital from January 2017 to December 2018 were retrospectively analyzed. The Results of laboratory examination, drug treatment plan and adverse events were collected and analyzed. Results The average age of 40 AIDS patients with cryptococcal meningitis was (40.54±15.42) years, the length of stay was (32.67±12.22) d, 30 cases (75%) were elevated intracranial pressure, 37 cases (92.5%) were positive for Cryptococcal neoformans antigen, 92.5% cases were positive for CSF culture, 31 cases (77.5%) were positive for CSF culture, and 92.5% cases were positive for ink smear in cerebrospinal fluid, respectively. Amphotericin B combined with fluorocytosine was selected as the treatment regimen in the induction period. During the treatment, the most adverse events were anemia in 22 cases (55.0%), followed by hypokalemia in 17 cases (42.5%); HGB and blood potassium indexes were significantly abnormal in the second week of drug use, and creatinine, total bilirubin and alanine aminotransferase indexes were significantly abnormal in the first week of drug use. The cumulative dose of amphotericin B > 500mg and HGB < 110 g/L before treatment were the influencing factors leading to the treatment course <14 d, and the difference was statistically significant (P=0.001, P=0.006). Conclusion There are different adverse events in the treatment of AIDS and cryptococcal meningitis at different time points during the treatment of amphotericin B. The main influence factors are cumulative dosage and HGB level before treatment.

Key words: amphotericin B, cryptococcal meningitis, adverse events

中图分类号: